A Phase 1 Study of ACTR087, an Autologous T Cell Product, in Combination with SEA-BCMA, a Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Protocol No
UNUM-ATTCK-17-01
Principal Investigator
Parameswaran Hari
Phase
I
Summary
Testing an experimental drug product called ACTR087 in combination with another experimental drug called SEA-BCMA to treat relapsed refractory Multiple Myeloma
Description
Study of ACTR087 in Combination with SEA-BCMA in Subjects with R/R MM
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: